Cloaking nanoparticles with protein corona shield for targeted drug delivery.
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index; 8 of the 31 sources its claims cite were checked for support.
Abstract
Targeted drug delivery using nanoparticles can minimize the side effects of conventional pharmaceutical agents and enhance their efficacy. However, translating nanoparticle-based agents into clinical applications still remains a challenge due to the difficulty in regulating interactions on the interfaces between nanoparticles and biological systems. Here, we present a targeting strategy for nanoparticles incorporated with a supramolecularly pre-coated recombinant fusion protein in which HER2-binding affibody combines with glutathione-S-transferase. Once thermodynamically stabilized in preferred orientations on the nanoparticles, the adsorbed fusion proteins as a corona minimize interactions with serum proteins to prevent the clearance of nanoparticles by macrophages, while ensuring systematic targeting functions in vitro and in vivo. This study provides insight into the use of the supramolecularly built protein corona shield as a targeting agent through regulating the interfaces between nanoparticles and biological systems.
Overview
CoChat Summary
## TL;DR
This paper presents a mesoporous silica nanoparticle coated with a supramolecularly pre-oriented GST-fusion affibody “protein corona shield” (PCSN) that reduces serum protein adsorption while preserving receptor targeting. In HER2-positive SK-BR3 models, PCSN showed reduced macrophage uptake and improved tumor accumulation and camptothecin delivery compared with PEG-MSN.
## Key findings
- PCSN construction was confirmed by multiple measures: surface charge shifted from about −40 mV for GSH-MSN to −5.3 mV for PCSN, hydrodynamic radius increased from about 140 ± 20 nm to 270 ± 20 nm, and the maximum loading of GST-HER2-Afb was 270 μg/mg.
- Serum protein adsorption was much lower on PCSN: after 1 h in 55% FBS, adsorbed protein band intensity was reported as about 15-fold lower than on GSH-MSN; PCSN also showed no significant change in hydrodynamic radius or surface charge after serum exposure.
- Proteomics identified 183 proteins on the particles; the 78 most abundant were analyzed, and PCSN had lower amounts of immune-response, complement, and coagulation proteins, with more apolipoproteins relative to GSH-MSN and PEG-MSN.
- In vivo, PCSN improved delivery and efficacy in SK-BR3 xenografts: tumor fluorescence was 1.8-fold higher than PEG-MSN at 0.5 h, 2.5-fold higher at 48 h, and PCSN(CPT) produced about 90.0% inhibition of tumor growth and 2.5-fold enhancement of inhibitory effects versus PEG-MSN(CPT).
## Methods
- The study built PCSN by supramolecularly attaching recombinant GST-HER2-Afb to glutathione-modified mesoporous silica nanoparticles; a randomized covalent version and a modified negative-control version were also prepared for comparison.
- In vitro analyses used SK-BR3, MDA-MB468, HEK293T, and RAW264.7 cells, with serum-protein adsorption assessed by SDS-PAGE, LC-MS/MS proteomics, DLS/zeta/PDI, microscopy, flow cytometry, and viability assays.
- In vivo work used female nude mice bearing SK-BR3 xenografts; biodistribution was tracked with DiD imaging and antitumor efficacy with camptothecin-loaded formulations given by intravenous injection.
## Limitations
- The paper itself notes that its in vivo efficacy data come from a specific HER2-positive SK-BR3 xenograft model with 6 mice per group for imaging and treatment groups of 6 mice per group; broader generalizability is not directly shown.
- The text makes evident that the work is largely a preclinical proof-of-concept study, so clinical safety and effectiveness in humans are not tested here (evident from the study design).
- The paper discusses mechanistic interpretation of protein corona composition and apolipoprotein recruitment, but a fully causal molecular mechanism for targeting is not definitively established in the provided text (evident from the discussion).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



![Fig. 4 Ex vivo and in vivo efficiency of PCSN. a, b Fluorescence images of organs and tumors 48 h after intravenous injection and biodistribution of injected formulations in animals with SK-BR3 tumor xenograft from fluorescence intensity analysis. In vivo antitumor effects in different treatment groups loaded with camptothecin (CPT) (1.5 mg/kg of mice) (scale bar is 2 cm). c Growth curve of tumor volume after intravenous injection with various groups of carriers until day 21 (n = 6 mice per group, mean ± 1 day [n = 6 mice per group, mean ± SD, statistical significance was calculated by one-way analysis of variance, *P < 0.05, **P < 0.01]](https://figures.cochat.ai/paper-figures/21a1e1814bad4b688dfc57e69101a199/cloaking-nanoparticles-with-protein-corona-shield-for-targeted-drug-delivery-figure-4.jpg)
Verification
Claims the paper makes
6 Valid · 1 Not valid · 7 Not checked · 47 Own results and interpretations
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“the addition of targeting ligands increased the clearance of nanoparticles by MPS”
§ Cloaking nanoparticles with protein corona shield for targeted drug delivery > Introduction
What the sources say
- Could not verifycites [8] Wilhelm, S. et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 16014 (2016). sourceExperimental — accuracy not yet measured
The Tumour targeting mechanism section says that active targeting adds ligands to nanoparticles, and Organs competing with tumours says the MPS clears circulating nanoparticles. Neither section links the addition of targeting ligands to increased MPS clearance. Searches for targeting ligands, macrophage uptake, and clearance found no passage making that comparison; the Macrophage uptake mechanisms section instead discusses size, charge, and PEG coatings. (LLM, conf=0.74)
- Could not verifycites [9] Monopoli, M. P., Aberg, C., Salvati, A. & Dawson, K. A. Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotechnol. 7, 779–786 (2012). sourceExperimental — accuracy not yet measured
Our copy of Monopoli et al. (2012) mentions grafted targeting ligands only twice: the introduction ('the biomolecular corona is also relevant to nanoparticles with grafted antibodies, proteins and peptides that are specifically designed for targeting in nanomedicine... Their presence may lead to more subtle and poorly understood biological consequences, issues possibly related to current struggles in achieving efficient targeting of nanomedicines in vivo') and Future Challenges ('Although grafting targeting ligands onto nanoparticles can reduce nonspecific binding of molecules from the environment... possibly even partly explaining the sometimes puzzling lack of success of some targeting strategies when applied in vivo'). Neither states that adding targeting ligands increases clearance by the mononuclear phagocyte system; searches for MPS/mononuclear phagocyte/reticuloendothelial, clearance, opsonization and macrophage uptake returned only generic corona-biodistribution text ('until final accumulation or clearance'), a surfactant-lipid-corona effect on macrophage uptake of carbon nanotubes, and reference titles (e.g. Karmali & Simberg 2011, ref 77, on plasma-protein interactions and clearance). The attributed mechanism is therefore not addressed by our copy, and the one directional statement it makes (ligand grafting can reduce nonspecific binding) is about adsorption of biomolecules, not MPS clearance. (LLM, conf=0.68)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“recent reports have revealed only a modest increase in tumor targeting when this approach is applied”
§ Cloaking nanoparticles with protein corona shield for targeted drug delivery > Introduction
What the sources say
- Supportedcites [8] Wilhelm, S. et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 16014 (2016). source
In “Delivery efficiency and consequences,” the paper reports a modest difference in tumour delivery efficiency between active and passive targeting (0.9% versus 0.6% of injected dose). “Intratumoural targeting” further reports no significant difference in tumour accumulation in head-to-head comparisons. (LLM, conf=0.92)
- Not checked yetcites [9] Monopoli, M. P., Aberg, C., Salvati, A. & Dawson, K. A. Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotechnol. 7, 779–786 (2012). source
Checked before — its earlier verdict is held back until a new check runs.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Considering that apolipoproteins on nanoparticle play an important role in association with cellular uptake to target cells32–34, targeting capability of PCSN partly could be linked with some serum proteins recruited at the surface of PCSN.”
§ Cloaking nanoparticles with protein corona shield for targeted drug delivery > Results and Discussion > The interaction between PCSN and serum proteins
What the sources say
- Not checked — no full text of the sourcecites [32] Pozzi, D. et al. Effect of polyethylene glycol (PEG) chain length on the bio–nano-interactions between PEGylated lipid nanoparticles and biological fluids: from nanostructure to uptake in cancer cells. Nanoscale 6, 2782–2792 (2014). source
- Not checked — no full text of the sourcecites [33] Caracciolo, G. Clinically approved liposomal nanomedicines: lessons learned from the biomolecular corona. Nanoscale 10, 4167–4172 (2018). source
- Supportedcites [34] Digiacomo, L. et al. An apolipoprotein-enriched biomolecular corona switches the cellular uptake mechanism and trafficking pathway of lipid nanoparticles. Nanoscale 9, 17254–17262 (2017). source
The Results and Discussion (page unavailable) identify apolipoproteins on the liposome corona and report that the corona switches the liposomes’ cellular uptake pathway. The Introduction (page unavailable) links apolipoproteins to LDL receptors. These passages support the cited premise that surface-recruited proteins can influence cellular uptake; the suggestion about PCSN is the citing authors’ own inference. (LLM, conf=0.88)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“covalent attachment of their counterparts on particles significantly changes their conformations and particle surface properties (e.g., hydrophobicity and charge density), inducing potential detrimental interactions with external biomolecules, rather than stabilizing them13,19,37.”
§ Cloaking nanoparticles with protein corona shield for targeted drug delivery > Results and Discussion > The interaction between PCSN and serum proteins
What the sources say
- Partly supportedcites [13] Salvati, A. et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat. Nanotechnol. 8, 137–143 (2013). sourceExperimental — accuracy not yet measured
The paper’s main text says surface-grafting may disrupt protein structure or constrain its orientation, and reports serum-protein binding to functionalized particles. It does not establish the claimed significant conformational changes or changes in hydrophobicity and charge density; for its transferrin particles, it says circular dichroism indicated that protein structure was largely preserved. The adverse interaction it demonstrates is serum-protein binding that compromises targeting, not a demonstrated consequence of those claimed changes. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [19] Mirshafiee, V., Kim, R., Park, S., Mahmoudi, M. & Kraft, M. L. Impact of protein pre-coating on the protein corona composition and nanoparticle cellular uptake. Biomaterials 75, 295–304 (2016). source
- Not checked yetcites [37] Herda, L. M., Hristov, D. R., Lo Giudice, M. C., Polo, E. & Dawson, K. A. Mapping of molecular structure of the nanoscale surface in bionanoparticles. J. Am. Chem. Soc. 139, 111–114 (2017). source
Checked before — its earlier verdict is held back until a new check runs.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The attachment of GST-HER2 on GSH-MSN was confirmed by measuring the surface charge, which changed from −40 mV (GSH-MSN) to −5.3 mV (PCSN) (Fig. 1c).”
§ Cloaking nanoparticles with protein corona shield for targeted drug delivery > Results and Discussion > The development of PCS on nanoparticle
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 61 claims and to verify the 4 references still open.
- Probably not a substantial claim. 4
- It may state two separate claims as one. 27
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Cloaking nanoparticles with protein corona shield for targeted drug delivery > Methods > In vivo and ex vivo fluorescence imaging
“To evaluate the biodistribution of GSH-MSN, PEG-MSN, and PCSN loaded with a lipophillic dye, DiD (at 10 wt% loading capacity) was intravenously injected (0.1 mg/mL) into SK-BR3 tumor-bearing nude mice (7 mice/group).”
§ Cloaking nanoparticles with protein corona shield for targeted drug delivery > Results and Discussion > Effect of PCSN on the targeting and antitumor efficacy
“To translate the outcomes of PCSN in an in vivo tumor model, nanoparticles loaded with the far-red fluorescent dye DiD were systemically injected via the tail vein into nude mice (n = 6 mice per group) bearing SK-BR3 cell xenografts, after which the tumor accumulation of PCSN was monitored.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“pretreated with different inhibitors, including sucrose (clathrin-mediated uptake, 400 nM), methyl-beta cyclodextrin (caveolae-mediated uptake), and amilorin (macropinocytosis), in a serum-free DMEM for 1 h”
§ Cloaking nanoparticles with protein corona shield for targeted drug delivery > Methods > Endocytic pathway analysis
Reported 400 · recomputed 0.0004
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Biomolecular coronas provide the biological identity of nanosized materials
Monopoli, M. P., Åberg, C., Salvati, A., & Dawson, K. A. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.207 · Cited by 3,017
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Maeda, H., Nakamura, H., & Fang, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.002 · Cited by 2,376
Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology
Tenzer, S., Docter, D., Kuharev, J., Musyanovych, A., Fetz, V., Hecht, R., Schlenk, F., Fischer, D., Kiouptsi, K., Reinhardt, C., et al. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2013.181 · Cited by 2,283
Salvati, A., Pitek, A. S., Monopoli, M. P., Prapainop, K., Bombelli, F. B., Hristov, D. R., Kelly, P. M., Åberg, C., Mahon, E., & Dawson, K. A. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2012.237 · Cited by 1,912
Walkey, C. D., & Chan, W. C. W. (2012) · Chem. Soc. Rev. · doi:10.1039/c1cs15233e · Cited by 1,758
Protein-nanoparticle interactions
Lynch, I., & Dawson, K. A. (2008) · Nano Today · doi:10.1016/s1748-0132(08)70014-8 · Cited by 1,727
Cited by
Active Targeting Strategies Using Biological Ligands for Nanoparticle Drug Delivery Systems
Yoo, J., Park, C., Yi, G., Lee, D., & Koo, H. (2019) · Cancers · doi:10.3390/cancers11050640 · Cited by 726
“successfully used Afbs for active targeting of NPs [20].”
MethodFoulkes, R., Man, E., Thind, J., Yeung, S., Joy, A., & Hoskins, C. (2020) · Biomaterials Science · doi:10.1039/d0bm00558d · Cited by 568
Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?
Vallet-Regí, M., Schüth, F., Lozano, D., Colilla, M., & Manzano, M. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00659b · Cited by 507
Qiu, M., Tang, Y., Chen, J., Muriph, R., Ye, Z., Huang, C., Evans, J., Henske, E. P., & Xu, Q. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2116271119 · Cited by 504
Kopac, T. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.12.108 · Cited by 418
Metadata
- Authors
- Oh, J. Y., Kim, H. S., Palanikumar, L., Go, E. M., Jana, B., Park, S. A., Kim, H. Y., Kim, K., Seo, J. K., Kwak, S. K., Kim, C., Kang, S., & Ryu, J.-H.
- Affiliations
- Ulsan National Institute of Science and Technology (KR)
- Corresponding author
- Kim, Chaekyu
- Kang, Sebyung
- Ryu, Ja-Hyoung
- ORCID
- Venue
- Nature communications
- Published
- 2018-10-31
- Volume
- 9
- Issue
- 1
- Pages
- 4548-4548
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC6208370
- OpenAlex
- W2898317973
- Cited by
- 409
- References
- 41
- Citations by year
- 2026: 23 · 2025: 47 · 2024: 35 · 2023: 48 · 2022: 80 · 2021: 70 · 2020: 72 · 2019: 32 · 2018: 1
- FWCI
- 14.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion, cc-by)
- Funders
- National Research Foundation of Korea (2015H1D3A1061983, 2018R1A6A1A03025810, 2016R1A5A1009405, 2017R1A2B4003617)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- protein corona, targeted drug delivery, nanoparticles, glutathione S-transferase, fusion protein, serum protein adsorption
- MeSH terms
- Protein Corona, RAW 264.7 Cells, Animals, Antineoplastic Agents, Blood Proteins, Female, Humans, Mice, Nude, Protein Binding, Drug Delivery Systems, Proteomics, Cell Line, Tumor, Mice, Nanoparticles, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cloaking nanoparticles with protein corona shield for targeted drug delivery. https://app.cochat.ai/papers/10.1038/s41467-018-06979-4
- The paper
- Oh, J. Y., Kim, H. S., Palanikumar, L., Go, E. M., Jana, B., Park, S. A., Kim, H. Y., Kim, K., Seo, J. K., Kwak, S. K., Kim, C., Kang, S., & Ryu, J.-H. (2018). Cloaking nanoparticles with protein corona shield for targeted drug delivery. Nature communications. https://doi.org/10.1038/s41467-018-06979-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.